BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data registry for the Rotarex™ Atherectomy System to measure real-world outcomes for patients with peripheral artery disease (PAD).
Known as 'XTRACT,' this prospective, multi-center, single-arm, post-market registry study will assess the clinical performance of the Rotarex™ Atherectomy System in the treatment of U.S. patients with PAD lesions. The XTRACT Registry is being led in partnership with Co-Principal Investigators, Dr. Prakash Krishnan, an interventional cardiologist, and Dr. Todd Berland, a vascular surgeon. The registry will enroll up to 600 patients at approximately 100 clinical sites across the United States, with the first patient enrollment expected later this year. Clinical follow-up evaluations will occur after 30 days, 6 months and 12 months post-procedure to assess safety and effectiveness of outcomes.
'This registry will provide valuable data to support clinical decision-making and enhance patient outcomes in the management of PAD,' said Dr. Krishnan. 'The Rotarex™ System has been extensively studied internationally, and we are excited to further evaluate its adaptability in treating a wide range of PAD lesions within the U.S. patient population.'
The Rotarex™ Atherectomy System is a minimally invasive solution designed to efficiently remove both plaque and thrombus in peripheral arteries. Offering dual indications as both an atherectomy and thrombectomy device, the Rotarex™ Atherectomy System is a proven tool for treating PAD.
'The XTRACT Registry is the first comprehensive registry aimed at providing key insights into the real-world applications of the Rotarex™ System,' said Rima Alameddine, worldwide president of BD Interventional-Peripheral Intervention. 'This study underscores our unwavering commitment to optimizing treatment strategies in partnership with leading physicians to improve patient care.'
PAD is a potentially debilitating disease that is estimated to affect more than 21 million Americans and more than 200 million people worldwide and can lead to increased risk of cardiovascular complications and lower limb amputation.1,2 The XTRACT Registry underscores BD's ongoing commitment to innovative technological development and evidence-based research that support physicians and improve patient outcomes.
About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts:
Media:
Investors:
Troy Kirkpatrick
Adam Reiffe
BD Public Relations
BD Investor Relations
858.617.2361
201.847.6927
Troy.Kirkpatrick@bd.com
adam.reiffe@bd.com
1 Yost, Mary. The Current U.S. Prevalence of Peripheral Arterial Disease. Vascular Disease Management. 2023;20(4):E67-E732 Allison MA, Armstrong DG, Goodney PP, et al. Health Disparities in Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2023;148:286-296. doi:10.1161/CIR.0000000000001153
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 hours ago
- Malaysian Reserve
Innovate, Collaborate, And Elevate Healthcare In ASEAN And Beyond
KUALA LUMPUR, Malaysia, June 2, 2025 /PRNewswire/ — International Healthcare Week (IHW) 2025, Southeast Asia's premier healthcare event, will be held from July 16 to 18 at the Malaysia International Trade and Exhibition Centre (MITEC), Kuala Lumpur. Organised by Informa Markets, IHW 2025 is set to be a transformative platform that accelerates healthcare innovation, fosters regional collaboration, and drives economic growth throughout the healthcare sector. With over 900 leading local, regional, and international exhibitors showcasing more than 15,000 products and services, and an expected attendance of 21,000 professionals from over 50 countries, IHW 2025 offers unmatched opportunities for networking, knowledge exchange, and business development. One Venue, Five Healthcare Trade Shows, One Unmissable Event IHW 2025 integrates five flagship international trade exhibitions under one roof, covering the entire healthcare value chain and enhancing opportunities to learn, collaborate, invest, and showcase innovations across healthcare sectors, noted Rungphech (Rose) Chitanuwat, Regional Portfolio Director – ASEAN at Informa Markets. Each exhibition is complemented by dedicated conferences tailored to the specific needs and developments of their respective industries: CPHI South East Asia – covering the complete pharmaceutical production supply chain. WHX Kuala Lumpur (formerly Asia Health) – focusing on medical devices, hospital services, and healthcare systems. WHX Labs Kuala Lumpur (formerly Medlab Asia) – the premier medical laboratory event in the region. Medtec Southeast Asia – specializing in the design and manufacturing of medical devices and technologies. HIMSS (Healthcare Information and Management Systems Society) – a leading global conference exploring key themes in digital health, including: Artificial Intelligence, Data Innovation, Workforce Transformation, and Equitable Care Delivery. 'Participants at IHW 2025 will have the unique advantage of exploring multiple healthcare sectors and attending 125 conference sessions tailored to diverse healthcare domains – all within a single venue. This integrated format eliminates the need to travel between separate events, allowing attendees to maximise their time and resources while gaining a comprehensive understanding of the latest market trends, innovative technologies, and cutting-edge solutions,' said Rungphech. Malaysia – Leading the Way in Healthcare 'Malaysia's robust healthcare market expansion, flourishing medical tourism sector, strategic regional location, supportive government initiatives, and ongoing advancements in healthcare infrastructure collectively establish the country as an ideal host for IHW 2025. This event will further cement Malaysia's status as a premier healthcare hub in ASEAN and serve as a gateway for global healthcare collaboration,' highlighted Rungphech. As ASEAN Chair in 2025, Malaysia plays a pivotal role in promoting regional healthcare cooperation, addressing critical challenges such as supply chain resilience, digital health adoption, and sustainable health financing through platforms like the EU-ASEAN Health Summit. Strengthening Regional Healthcare Cooperation IHW 2025 is fully aligned with ASEAN's strategic objectives to bolster healthcare systems, enhance health outcomes, and promote equitable access across member states. The event serves as a vital platform for fostering networking and partnerships essential for advancing cross-border collaboration, policy harmonization, and increased investment in healthcare infrastructure and services. This collaborative environment supports key regional initiatives including digital health integration, combating non-communicable diseases, and pandemic preparedness-priorities underscored by recent public health challenges in Southeast Asia. MATRADE: A Strong and Strategic Partner As a valued partner of International Healthcare Week 2025, the Malaysia External Trade Development Corporation (MATRADE), Malaysia's national trade promotion agency, plays a crucial role in enhancing Malaysia's global visibility and reputation in the healthcare sector. Through promotion and fostering international collaborations, MATRADE actively positions Malaysia as a regional medical hub for Southeast Asia and beyond. YB Dato' Seri Reezal Merican Naina Merican, Chairman of MATRADE, emphasized the significance of IHW 2025, stating, 'International Healthcare Week serves as a powerful platform that elevates Malaysia's standing as a regional leader in healthcare and medical services. This leading event not only promotes innovation but also directly contributes to our nation's economic growth by attracting world-class exhibitors, regional and international delegates, and top healthcare experts to Malaysia—fueling trade, knowledge sharing, and industry advancement.' Join Us at IHW 2025 Healthcare professionals are invited to register online at to secure their place at this free-to-attend event. Don't miss this exceptional opportunity to contribute to shaping the future of the vibrant and evolving healthcare industry in ASEAN and beyond! About Informa Markets Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. We provide marketplace participants around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, targeted digital services and actionable data solutions. We connect buyers and sellers across more than a dozen global verticals, including Pharmaceuticals, Boating, Food, Fashion, and Infrastructure. As the world's leading market-making company, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year.
Malaysian Reserve
10 hours ago
- Malaysian Reserve
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2b CORAL trial of Haduvio in patients with IPF chronic cough. Conference Call/WebcastThe Company will host a conference call and webcast to review the topline results. The live webcast, including audio and presentation slides, will be accessible at the time of the meeting and can be accessed here. To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About Idiopathic Pulmonary Fibrosis (IPF) Chronic CoughChronic cough is a highly prevalent condition in patients with IPF, impacting up to 85% of the IPF population. There are ~140,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Investor ContactJonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media ContactRosalia Scampoli914-815-1465rscampoli@
Malaysian Reserve
12 hours ago
- Malaysian Reserve
Viatris Deadline: VTRS Investors with Losses in Excess of $100K Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit
NEW YORK, June 1, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the 'Class Period'), of the important June 3, 2025 lead plaintiff deadline. So what: If you purchased Viatris securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Viatris class action, go to call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 3, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, during the Class Period, defendants provided investors with material information concerning the failed inspection of Viatris' Indore, India facility. Defendants' statements, albeit made months after the initial inspection and defendants' initiation of remediation efforts included, among other things, the disclosure of the FDA's issuance of a warning letter and import alert which would prevent Viatris from shipping eleven products from the Indore facility, though four of such were exempt from the limitations (the 'Warning Letter'). Defendants routinely referred to the impact of the Warning Letter as a mere 'minor headwind' for Viatris. Further, defendants provided these disclosures to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state impact of the Warning Letter on Viatris' financials. Notably, defendants did not disclose precisely when the inspection occurred, how long the remediation efforts had been implemented, or the financial impact of the existing and continued remediation efforts. Defendants further notably failed to disclose which products were subject to the FDA Warning Letter, which products were subject to exemptions, and the significance of the restricted products with respect to Viatris' existing financials and future projections, and for which Viatris believed it would obtain exemptions. Such statements, absent these material facts, caused Plaintiff and other shareholders to purchase Viatris' securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Viatris class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email case@ for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Kim, Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827case@
